v3.26.3
SEGMENT INFORMATION
 12 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
SEGMENT INFORMATION

(13) SEGMENT INFORMATION

 

The Company views its operations and manages its business in one operating segment: life science. The table below summarizes the significant expense categories for the life science segment regularly provided to the Company’s Chief Financial Officer / Chief Operating Officer (the “CFO / COO”), its Chief Operating Decision Maker (the “CODM”).

 

The accounting policies of the Company’s segment are the same as those described in the summary of significant accounting policies. The CODM assesses performance for its segment based on net loss, which is reported on the consolidated statements of operations. The measure of segment assets is reported on the balance sheet as total assets. The CODM uses cash forecast models in deciding how to invest in the segment. The CODM analyzes the Company’s net loss and monitors budget versus actual results to assess the performance of the Company.

 

   2026   2025 
   Year Ended June 30, 
   2026   2025 
Total Revenues  $13,185,031   $- 
Less:          
Program spend   6,066,487    8,548,616 
Personnel costs   10,313,404    9,496,251 
Administrative costs  (a)   5,473,428    4,662,973 
Gain on Sale of Vyleesi   -    (3,130,000)
Gain on Purchase Commitment   -    (2,117,900)
Other segment items (b)   (290,393)   (152,591)
Segment net loss  $(8,377,895)  $17,307,349 

 

(a)Contains depreciation and amortization. Depreciation was $62,679 and $258,917 for the years ended June 30 2026 and 2025, respectively
(b)Other segment items include investment income, interest expense and foreign currency (gain) loss, which are disclosed in the consolidated financial statements.